On October 29, 2021 Prescient Therapeutics Limited (ASX: PTX) reported that it has released the results for September quarter of fiscal year 2022 (Press release, Prescient Therapeutics, OCT 29, 2021, View Source;utm_medium=rss&utm_campaign=prescient-closes-very-productive-september-quarter-with-strong-cash-position [SID1234592169]). The ASX-listed clinical stage oncology company continues to stand strong with excellent financial performance. Several anti-cancer programs of the firm are progressing in the right direction towards multiple value creating milestones.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
With prudent financial management, Prescient ended the quarter with a strong cash position. Below are the key points from its quarterly report:
The firm had a cash balance of AU$14.8 million at quarter end.
Net cash outflows for the quarter were AU$1.2 million, with AU$0.782 million invested in research and development across Australia and the United States.
Several investments were made in the ongoing clinical studies of PTX-100 and PTX-200; pre-clinical development of the OmniCAR platform as well as Cell Therapy Enhancements.
Progress made so far in different therapy programs
Internal OmniCAR Programs: During the reporting period, Prescient received positive in silico results from immunogenicity testing of OmniCAR’s key binding components, SpyTag and SpyCatcher.
Immunogenicity evluates the immune response against a new therapy and the overall safety profile of a new treatment. There can be adverse impacts on CAR-T cell expansion due to increased levels of immunogenicity. In this case, the test outcome was positive as it detected low immunogenicity equivalent to circulating human antibodies.
Prescient Therapeutics (ASX:PXT)
Cell Therapy Enhancement Program: The Cell Therapy Enhancement (CTE) program is maturing well to achieve several striking pre-clinical milestones. The program is being conducted under the guidance of a world-leading research team at the Peter MacCallum Cancer Centre in Melbourne.
The result obtained so far hint at great scope for cancer treatment by enhancing current generation cell therapy approaches. It also holds possibility for next-generation approaches.
PTX-100: Phase 1b results from the PTX-100 basket trial confirmed it to be an excellent safety profile, with no serious adverse events related to the drug. Of particular interest was the efficacy signal observed in two patients with highly aggressive T cell lymphomas. Now, an expansion cohort study will be conducted for PTX-100, focusing on T cell lymphomas, with a potential for subsequent registration study.
Peripheral T cell lymphoma in particular is a cancer of considerable unmet need and represents a potential shorter path to market for PTX100.
PTX-200: The Phase 1b clinical study of PTX-200 and cytarabine in patients with acute myeloid leukemia is screening patients for a higher dose level of 45 mg/m2. No results were posted during the quarter.
Prescient strengthened its Board to advance its OmniCAR GMB program
An acknowledged expert in the treatment of glioblastoma multiforme (GMB), Professor Donald M. O’Rourke has been appointed as a member of the Prescient’s growing international Scientific Advisory Board.
Professor O’Rourke is a tenured Professor at the Department of Neurosurgery in the Perlman School of Medicine at the University of Pennsylvania and the Abramson Cancer Centre where he holds the John Templeton Jr MD Chair in Neurosurgery.
To know more about Prescient Therapeutics Limited, click here.
To stay updated with PTX company activities and announcements, please update your details on their investor centre.